# Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

> **NCT07199413** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 20 (estimated)

## Conditions studied

- Brain Metastases
- Leptomeningeal Metastasis

## Interventions

- **BIOLOGICAL:** SV-BR-1-GM Vaccine
- **DRUG:** Cyclophosphamide
- **DRUG:** Pembrolizumab
- **DRUG:** Interferon

## Key facts

- **NCT ID:** NCT07199413
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2029-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07199413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07199413, "Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07199413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*